Table 3 Standardised incidence ratios and absolute excess risks of subsequent primary neoplasm subtypes among patients with bone sarcoma in Sweden.
Overall | Osteosarcoma | Ewing sarcoma | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Types of subsequent primary neoplasms | Person years | No. Obs/exp | SIR (95% CI) | AER (95% CI) | No. Obs/exp | SIR (95% CI) | AER (95% CI) | No. Obs/exp | SIR (95% CI) | AER (95% CI) |
Any | 19,170 | 104/47.2 | 2.2 (1.8–2.7) | 35.1 (23.3–48.7) | 75/40.4 | 1.9 (1.4–2.5) | 30.7 (16.5–47.5) | 29/6.8 | 4.2 (2.8–6.1) | 45.4 (25.8–71.3) |
Breast | 7169 | 18/7.1 | 2.5 (1.5–4.0) | 15.2 (5.0–29.8) | 12/5.8 | 2.1 (1.1–3.6) | 12.1 (0.7–29.6) | 6/1.3 | 4.7 (1.7–10.2) | 23.0 (4.5–57.3) |
Bone | 16,905 | 2/0.2 | 13.7 (1.7–49.7) | 1.1 (0.1–4.2) | 0/0.1 | – | – | 2/0.0 | 47.7 (5.8–172) | 3.9 (0.4-14.2) |
Soft tissue | 16,826 | 8/0.4 | 20.6 (8.9–40.5) | 4.5 (1.8–9.1) | 3/0.3 | 9.5 (2.0–27.8) | 2.3 (0.3–7.2) | 5/0.1 | 67.3 (21.9–157) | 9.8 (3.1–23.1) |
Haematologic | 16,874 | 10/4.4 | 2.3 (1.1–4.2) | 3.3 (0.2–8.3) | 6/3.7 | 1.6 (0.6–3.5) | 1.9 (−1.3 to 7.9) | 4/0.7 | 5.6 (1.5–14.4) | 6.5 (0.7–18.9) |
Skin | 16,793 | 13/5.7 | 2.3 (1.2–3.9) | 4.3 (0.7–9.8) | 12/4.9 | 2.5 (1.3–4.3) | 6.1 (1.1–13.7) | 1/0.9 | 1.2 (0.0–6.5) | 0.3 (−1.6 to 9.3) |
CNS | 16,815 | 11/2.3 | 4.8 (2.4–8.6) | 5.2 (1.9–10.3) | 11/1.8 | 6.3 (3.1–11.2) | 7.9 (3.2–15.3) | 0/0.5 | – | – |
Digestive tract | 16,877 | 7/9.4 | 0.7 (0.3–1.5) | −1.4 (−3.9 to 3.0) | 5/8.4 | 0.6 (0.2–1.4) | −2.9 (−5.7 to 2.8) | 2/1.0 | 2.0 (0.2–7.2) | 2.0 (−1.5 to 12.3) |
Genitourinary | 16,838 | 17/11.8 | 1.4 (0.8–2.3) | 3.1 (−1.1 to 9.2) | 15/10.5 | 1.4 (0.8–2.4) | 3.8 (−1.8 to 12.1) | 2/1.3 | 1.5 (0.2–5.6) | 1.4 (−2.1 to 11.7) |
Female genital | 7128 | 10/3.2 | 3.1 (1.5–5.8) | 9.5 (2.4–21.5) | 7/2.6 | 2.7 (1.1–5.5) | 8.6 (0.3–23.2) | 3/0.6 | 5.4 (1.1–15.7) | 11.9 (0.3–40.0) |
Other | 16,846 | 19/7.6 | 2.5 (1.5–3.9) | 6.8 (2.3–13.1) | 13/6.6 | 2.0 (1.1–3.4) | 5.5 (0.3–13.3) | 6/1.0 | 6.0 (2.2–13.1) | 9.9 (2.4–23.9) |
